FY2025 Earnings Forecast for CLDX Issued By HC Wainwright

Celldex Therapeutics, Inc. (NASDAQ:CLDX) – HC Wainwright dropped their FY2025 earnings estimates for Celldex Therapeutics in a report released on Tuesday, November 11th. HC Wainwright analyst J. Pantginis now anticipates that the biopharmaceutical company will post earnings per share of ($3.67) for the year, down from their prior estimate of ($3.34). HC Wainwright currently has a “Buy” rating and a $42.00 price objective on the stock. The consensus estimate for Celldex Therapeutics’ current full-year earnings is ($2.48) per share. HC Wainwright also issued estimates for Celldex Therapeutics’ Q4 2025 earnings at ($1.03) EPS.

Other analysts also recently issued research reports about the stock. Citigroup reduced their price target on shares of Celldex Therapeutics from $56.00 to $48.00 and set a “buy” rating for the company in a research report on Wednesday, August 20th. Canaccord Genuity Group reiterated a “buy” rating and set a $62.00 target price on shares of Celldex Therapeutics in a report on Wednesday, September 17th. Mizuho initiated coverage on shares of Celldex Therapeutics in a research note on Tuesday, October 21st. They set an “outperform” rating and a $48.00 price objective on the stock. Barclays decreased their target price on shares of Celldex Therapeutics from $25.00 to $21.00 and set an “underweight” rating on the stock in a research report on Tuesday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Celldex Therapeutics in a report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $43.80.

Celldex Therapeutics Price Performance

Shares of CLDX stock traded down $0.02 during trading on Thursday, reaching $24.23. The company’s stock had a trading volume of 133,419 shares, compared to its average volume of 1,015,047. Celldex Therapeutics has a 1-year low of $14.40 and a 1-year high of $29.05. The company has a market capitalization of $1.61 billion, a price-to-earnings ratio of -8.07 and a beta of 1.36. The stock’s 50-day moving average price is $25.49 and its 200 day moving average price is $22.82.

Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings data on Monday, November 10th. The biopharmaceutical company reported ($1.01) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.13). Celldex Therapeutics had a negative return on equity of 27.61% and a negative net margin of 3,446.88%.

Institutional Investors Weigh In On Celldex Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Handelsbanken Fonder AB grew its position in Celldex Therapeutics by 2.4% in the second quarter. Handelsbanken Fonder AB now owns 21,600 shares of the biopharmaceutical company’s stock valued at $440,000 after acquiring an additional 500 shares during the period. Russell Investments Group Ltd. boosted its position in Celldex Therapeutics by 27.6% during the second quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock valued at $47,000 after purchasing an additional 501 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Celldex Therapeutics by 1.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,451 shares of the biopharmaceutical company’s stock valued at $798,000 after purchasing an additional 680 shares during the last quarter. AlphaQuest LLC boosted its holdings in shares of Celldex Therapeutics by 7.0% during the 2nd quarter. AlphaQuest LLC now owns 12,956 shares of the biopharmaceutical company’s stock worth $264,000 after buying an additional 844 shares during the period. Finally, Nisa Investment Advisors LLC increased its stake in shares of Celldex Therapeutics by 171.7% during the second quarter. Nisa Investment Advisors LLC now owns 1,394 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 881 shares during the period.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.